Systemic inflammatory markers have independent prognostic value in patients with metastatic testicular germ cell tumours undergoing first-line chemotherapy

Fankhauser, Christian Daniel; Sander, Sophia; Roth, Lisa; Groß, Oliver; Eberli, Daniel; Sulser, Tullio; Seifert, Burkhardt; Beyer, Jörg; Hermanns, Thomas

doi:10.1038/bjc.2017.467

Cited by 70 publications

(69 citation statements)

References 35 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This tool recognized never relapsing and never dying patients and identified a poor prognostic group, where none of the relapsed patients were salvageable with treatment (Chovanec et al ., ,,). Simultaneously, Fankhauser et al ., () reported the same findings on SII together with the prognostic significance of neutrophils, neutrophil‐to‐lymphocyte ratio and c‐reactive protein.…”

Section: Emerging Immune Biomarkers and Immunotherapy In Gctssupporting

confidence: 61%

Immune mechanisms and possible immune therapy in testicular germ cell tumours

2019

View full text Add to dashboard Cite

Background: Testicular germ cell tumours (GCTs) are the only universally curable solid malignancy. The long-term cure rate of >95% is attributed to the extraordinary sensitivity to cisplatin-based treatment but a proportion of patients die due to a progression of the chemotherapy-refractory disease. While treatment of a variety of solid cancers was significantly improved with recent immune therapies, the immunology and immunotherapy remained underinvestigated in GCTs. Objectives: In this narrative review, we summarize evidence about immune-related mechanisms and possible immune therapies in GCTs and provide insights and implications for future research and clinical practice. Materials and methods: We performed a comprehensive search of PubMed/MEDLINE to identify original and review articles reporting on immune mechanisms and immunotherapy in GCTs. Review articles were further searched for additional original articles. Results: Clear link of immune surveillance and the presence of GCT have been identified with several novel immune-related prognostic biomarkers published recently. Several case reports, case series, and preliminary results from phase I-II studies are emerging to report on the efficacy of immune checkpoint inhibitors. Discussion: Newly discovered immune biomarkers provide an evidence supporting the role of immune environment in the GCT biology. While these discoveries provide only an initial insight into the immunobiology, strong correlation with prognosis is evident. This provided a premise to investigate the treatment efficacy of novel immunotherapy. Some efficacy of these treatments has been reported in clinical setting; however, the results of published studies with immune checkpoint inhibitor monotherapy seem to be disappointing. Conclusion: Immune-related mechanisms and efficacy of immune checkpoint blockade in GCTs should be further investigated in preclinical and clinical studies.

show abstract

Section: Emerging Immune Biomarkers and Immunotherapy In Gctssupporting

confidence: 61%

Immune mechanisms and possible immune therapy in testicular germ cell tumours

2019

View full text Add to dashboard Cite

show abstract

“…In this issue of the British Journal of Cancer, two articles highlight for the first time the prognostic significance of SII in patients with GCT. Fankhauser et al (2018) evaluated the prognostic value of SII in patients with metastatic GCT treated with cisplatin-based chemotherapy. The neutrophilto-lymphocyte ratio (NLR) was also calculated.…”

mentioning

confidence: 99%

Systemic immune-inflammation index in germ-cell tumours: search for a biological prognostic biomarker

Albany

2018

Br J Cancer

View full text Add to dashboard Cite

“…Recent studies have shown that the systemic inflammatory response can induce malignant tumor behavior and lead to shorter survival durations in patients with malignant solid tumors, and can also predict the prognosis of cancer (18)(19)(20)(21). SII as a novel systemic immune-inflammation index, that represents the overall inflammatory, and immune status of the patient has proven to be a meaningful preoperative biomarker in various tumors (18,(20)(21)(22). Hu et al found that in hepatocellular carcinoma SII was associated with circulating tumor cell levels and local recurrence (21), while Wang et al noted that SII was associated with age, tumor invasion, local lymph node metastasis, and distant metastasis in gastric cancer (18).…”

Section: Discussionmentioning

confidence: 99%

Prognostic Value of Preoperative Systemic Immune-Inflammation Index in Breast Cancer: A Propensity Score-Matching Study

et al. 2020

View full text Add to dashboard Cite

Purpose: It was reported that the novel preoperative systemic immune-inflammation index (SII) can predict survival in cases of many malignant tumors. However, the prognostic significance of preoperative SII in breast cancer remains unclear. The purpose of this study was to investigate the relationship between SII and survival in breast cancer patients.Methods: Breast cancer patients (1,026) who underwent a mastectomy at Sun Yat-sen University Cancer Center were retrospectively studied. The SII was determined using the following formula: neutrophil count × platelet count/lymphocyte count. The receiver operating characteristic (ROC) curve was used to determine the optimal cut-off value for SII. Propensity score matching (PSM) was applied to develop comparable cohorts of high SII group and low SII group.Results: A total of 1,026 patients were included as the primary cohort, and 894 patients were matched and regarded as the matched cohort. Patients were divided into two groups based on SII value: SII<601.7 and high SII >601.7. In the primary cohort, the 5-years overall survival (OS), recurrence-free survival (RFS), and distant metastasis-free survival (DMFS) rates for high SII group and low SII group were (85.6% vs. 91.3%, P = 0.016), (95.8% vs. 96.4%, P = 0.684), and (83.5% vs. 90.6%, P = 0.007), respectively. Univariate analysis showed that histological type, T stage, N stage, PR, HER2, Ki67, and SII all showed significant associations with OS; and histological type, T stage, N stage, and SII all showed significant associations with DMFS. Multivariate survival analysis revealed that SII can independently predict OS (P = 0.017) and DMFS (P = 0.007). Similar results were found in PSM cohort.Conclusions: Preoperative SII may be a reliable predictor of OS and DMFS in patients with operable breast cancer to provide personalized prognostication and assist in formulation of the clinical treatment strategy.

show abstract

Systemic inflammatory markers have independent prognostic value in patients with metastatic testicular germ cell tumours undergoing first-line chemotherapy

Abstract: Systemic inflammatory markers might have prognostic utility for patients with metastatic GCT. The planned IGCCCG update could be an opportunity to test these markers in a larger data set.

Cited by 70 publications

References 35 publications

Immune mechanisms and possible immune therapy in testicular germ cell tumours

Immune mechanisms and possible immune therapy in testicular germ cell tumours

Systemic immune-inflammation index in germ-cell tumours: search for a biological prognostic biomarker

Prognostic Value of Preoperative Systemic Immune-Inflammation Index in Breast Cancer: A Propensity Score-Matching Study

Contact Info

Product

Resources

About